Jamil Azzi is a transplant immunologist at Brigham and Women’s Hospital and Harvard Medical School. After receiving a clinical fellowship in Nephrology and Transplant Nephrology from Brigham and Women’s Hospital and Massachusetts General Hospital in Boston he completed a postdoctoral fellowship in immunology at the Transplantation Research Center at Harvard Medical School and joined faculty in 2011. In his laboratory at Harvard Medical School, he is interested in investigating the signaling pathways that control the balance between effector and regulatory T cells (Tregs) in Type 1 diabetes and transplantation. Tregs play a pivotal role in the maintenance of immune tolerance and hold great promise as cell therapy for a variety of immune-mediated diseases.
Azzi's laboratory is also interested in establishing novel therapeutic strategies in transplantation and in type 1 diabetes using nanotechnology. The past decade has witnessed major advancements in the development of new immunosuppressive drugs. The number of patients experiencing the toxicity associated with the use of these drugs, however, has also increased dramatically. Drug delivery techniques using nanotechnology provides therapeutic modalities with improved efficacy and reduced side effects.